Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

Pharmacogenomics

Volumn 17, Issue 7, 2016, Pages 731-741

  Lopez Lopez, Elixabet ^a   Gutierrez Camino, Angela ^a   Astigarraga, Itziar ^b   Navajas, Aurora ^b   Echebarria Barona, Aizpea ^b   Garcia Miguel, Purificacion ^c   Garcia De Andoin, Nagore ^d   Lobo, Carmen ^d   Guerra Merino, Isabel ^e   Martin Guerrero, Idoia ^a   Garcia Orad, Africa ^a,f  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL TXAGORRITXU   (Spain)

^f BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

acute lymphoblastic leukemia; neurotoxicity; pharmacokinetics; polymorphism; vincristine

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAUNORUBICIN; HYDROCORTISONE; METHOTREXATE; MICRORNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CEP72 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ABCB1 GENE; ABCC1 GENE; ABCC10 GENE; ABCC2 GENE; ABCC3 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC MARKER; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRESCHOOL CHILD; RALBP1 GENE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SPANIARD; GENETICS; METABOLISM; NEUROTOXICITY SYNDROMES; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS; MICROTUBULE-ASSOCIATED PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEINS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 84973572524     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0001     Document Type: Article

References (41)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166-178 (2006).
2. Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin. Drug Metab. Toxicol. 10(3), 483-494 (2014).
3. Carozzi VA, Canta A, Chiorazzi A, Cavaletti G. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci. Lett. 596, 90-107 (2015).
4. Ceppi F, Langlois-Pelletier C, Gagne V et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15(8), 1105-1116 (2014).
5. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ. Long-term effects of vincristine on the peripheral nervous system. J. Neurooncol. 15(1), 23-27 (1993).
6. Diouf B, Crews KR, Lew G et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313(8), 815-823 (2015).
7. Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet. Genomics 26(2), 100-102 (2016)
8. Lopez-Lopez E, Ballesteros J, Pinan MA et al. Polymorphisms in the methotrexate transport pathway: A new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet. Genomics 23(2), 53-61 (2013).
9. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 34(8), 1317-1327 (2006).
10. Leveque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J. Clin. Pharmacol. 47(5), 579-588 (2007).
11. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem. Pharmacol. 71(12), 1695-1704 (2006).
12. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 69(1),178-184 (2009).
13. Drake KJ, Singhal J, Yadav S et al. RALBP1/RLIP76 mediates multidrug resistance. Int. J. Oncol. 30(1), 139-144 (2007).
14. Egbelakin A, Ferguson MJ, MacGill EA et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 56(3), 361-367 (2011).
15. Moore AS, Norris R, Price G et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. J. Paediatr. Child Health 47(12), 875-882 (2011).
16. Hartman A, van Schaik RH, van der Heiden IP et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk. Res. 34(2), 154-159 (2010).
17. Plasschaert SL, Groninger E, Boezen M et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 76(3), 220-229 (2004).
18. Lopez-Lopez E, Gutierrez-Camino A, Pinan MA et al. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS ONE 9(3), e91261 (2014).
19. The Pharmacogenetics Knowledge Base. www.pharmgkb.com
20. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414-417 (2012).
21. International HapMap Project. http://hapmap.ncbi.nlm.nih.gov/
22. Haploview. www.broad.mit.edu/mpg/haploview/
23. Ensembl. www.ensembl.org/
24. F-SNP. http://compbio.cs.queensu.ca/F-SNP/
25. FastSNP. http://fastsnp.ibms.sinica.edu.tw
26. PolymiRTS Database 3.0. http://compbio.uthsc.edu/miRSNP/
27. Ziebarth JD, Bhattacharya A, Chen A, Cui Y. PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res. 40(Database issue), D216-D221 (2012).
28. Patrocles. www.patrocles.org/
29. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D. Patrocles: A database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res. 38(Database issue), D640-D651 (2010).
30. microRNA.org-Targets and expression. www.microrna.org/microrna/home.do
31. miRNA-SNiPer database. www.integratomics-time.com/miRNA-SNiPer
32. Zorc M, Skok DJ, Godnic I et al. Catalog of microRNA seed polymorphisms in vertebrates. PLoS ONE 7(1), e30737 (2012).
33. dbSNP-National Center for Biotechnology Information. www.ncbi.nlm.nih.gov/snp/
34. Sambrook J, Russell D. Molecular Cloning: A Laboratory Manual (3rd Edition). CSHL Press, NY, USA (2001).
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. 57, 289-300 (1995).
36. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 296(5576), 2225-2229 (2002).
37. Folmer Y, Schneider M, Blum HE, Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 14(11), 875-884 (2007).
38. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55(5), 929-937 (1999).
39. Liu Z, Qiu M, Tang QL, Liu M, Lang N, Bi F. Establishment and biological characteristics of oxaliplatinresistant human colon cancer cell lines. Chin. J. Cancer 29(7), 661-667 (2010).
40. Semsei AF, Erdelyi DJ, Ungvari I et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol. Int. 36(1), 79-86 (2012).
41. Gregers J, Green H, Christensen IJ et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 15(4), 372-379 (2015).